Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center


Study explores new urinary tract infection treatment

Submitted by sobecksm on

Vanderbilt's Neil Osheroff, PhD, is part of an international research collaboration resulting in what is on track to be the first new antibiotic treatment for uncomplicated urinary tract infections in more than 20 years.

https://news.vumc.org/2023/02/02/study-explores-new-urinary-tract-infection-treatment/
VUMC News & Communications
Locked

Research fellowship for genetic counselors established at Vanderbilt

Submitted by robbikm2 on

Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.

https://news.vumc.org/2023/10/03/research-fellowship-for-genetic-counselors-established-at-vanderbilt/
Bill Snyder
Locked

New members of Academy for Excellence in Clinical Medicine selected

Submitted by sobecksm on

Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.

https://news.vumc.org/2023/12/15/new-members-of-academy-for-excellence-in-clinical-medicine-selected/
Kathy Whitney
Locked

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Submitted by sobecksm on
Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.
https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/
Amy Wolf
Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Submitted by robbikm2 on

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/
Tom Wilemon
Locked

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.